Quick Answer
Royalty Pharma plc reported Cash and Equivalents of $618.70 million for fiscal year 2025.
Royalty Pharma plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $618.70M | -33.4% |
| 2024 | $929.03M | +94.8% |
| 2023 | $477.01M | -72.1% |
| 2022 | $1.71B | +11.0% |
| 2021 | $1.54B | +52.8% |
| 2020 | $1.01B | +309.7% |
| 2019 | $246.20M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $938.94M | -1.2% | +48.6% |
| June 30, 2025 | $631.91M | -64.2% | -41.9% |
| March 31, 2025 | $1.09B | +29.0% | +17.1% |
| December 31, 2024 | $929.03M | +94.8% | -2.2% |
| September 30, 2024 | $950.05M | +1.5% | -46.2% |
| June 30, 2024 | $1.76B | -18.8% | +109.3% |
| March 31, 2024 | $843.00M | -57.3% | +76.7% |
| December 31, 2023 | $477.01M | -72.1% | -49.1% |
- Royalty Pharma plc showed a decrease of -33.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Royalty Pharma plc’s cash and equivalents has grown by 151.3% (from $246.20 million to $618.70 million).
- The most recent figure is from Royalty Pharma plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: